

Pilar Brito-Zerán

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7667903/publications.pdf>

Version: 2024-02-01

111
papers

10,631
citations

41258

49
h-index

32761

100
g-index

117
all docs

117
docs citations

117
times ranked

10285
citing authors

#	ARTICLE	IF	CITATIONS
1	Adult haemophagocytic syndrome. <i>Lancet, The</i> , 2014, 383, 1503-1516.	6.3	1,013
2	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 20-28.	0.5	817
3	Autoimmune Diseases Induced by TNF-Targeted Therapies. <i>Medicine (United States)</i> , 2007, 86, 242-251.	0.4	624
4	Sjögren syndrome. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16047.	18.1	511
5	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.5	307
6	Autoimmune diseases induced by TNF-targeted therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 847-861.	1.4	260
7	Primary Sjogren syndrome. <i>BMJ, The</i> , 2012, 344, e3821-e3821.	3.0	254
8	The clinical spectrum of IgG4-related disease. <i>Autoimmunity Reviews</i> , 2014, 13, 1203-1210.	2.5	248
9	Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy. <i>Medicine (United States)</i> , 2011, 90, 359-371.	0.4	247
10	Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 256-264.	1.6	244
11	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	1.8	229
12	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.5	225
13	Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , 2015, 54, 2230-2238.	0.9	220
14	The clinical spectrum of autoimmune congenital heart block. <i>Nature Reviews Rheumatology</i> , 2015, 11, 301-312.	3.5	209
15	Systemic and organ-specific immune-related manifestations of COVID-19. <i>Nature Reviews Rheumatology</i> , 2021, 17, 315-332.	3.5	194
16	Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). <i>Rheumatology</i> , 2014, 53, 321-331.	0.9	187
17	Vasculitis in Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2006, 85, 95-104.	0.4	183
18	Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. <i>British Journal of Rheumatology</i> , 2005, 44, 89-94.	2.5	163

#	ARTICLE	IF	CITATIONS
19	Sarcoidosis in Patients With Chronic Hepatitis C Virus Infection. <i>Medicine (United States)</i> , 2005, 84, 69-80.	0.4	157
20	Topical and systemic medications for the treatment of primary Sjögren's syndrome. <i>Nature Reviews Rheumatology</i> , 2012, 8, 399-411.	3.5	152
21	Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. <i>Lupus</i> , 2008, 17, 281-288.	0.8	149
22	Diagnostic Approach to the Complexity of IgG4-Related Disease. <i>Mayo Clinic Proceedings</i> , 2015, 90, 927-939.	1.4	148
23	Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. <i>Rheumatology</i> , 2007, 46, 1359-1362.	0.9	139
24	Systemic Autoimmune Diseases in Patients with Hepatitis C Virus Infection: Characterization of 1020 Cases (The HISPAMEC Registry). <i>Journal of Rheumatology</i> , 2009, 36, 1442-1448.	1.0	139
25	A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases. <i>Medicine (United States)</i> , 2008, 87, 345-364.	0.4	136
26	Google-driven search for big data in autoimmune geoepidemiology: Analysis of 394,827 patients with systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2015, 14, 670-679.	2.5	135
27	Therapeutic approach to IgG4-related disease. <i>Medicine (United States)</i> , 2016, 95, e4002.	0.4	131
28	Acute Viral Infections in Patients With Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2008, 87, 311-318.	0.4	128
29	The Overlap of Sjögren's Syndrome with Other Systemic Autoimmune Diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 36, 246-255.	1.6	122
30	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 137-156.	1.3	118
31	Atypical Autoantibodies in Patients with Primary Sjögren Syndrome: Clinical Characteristics and Follow-Up of 82 Cases. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 35, 312-321.	1.6	106
32	Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1255-1271.	1.0	106
33	Life-Threatening Cryoglobulinemia: Clinical and Immunological Characterization of 29 Cases. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 36, 189-196.	1.6	98
34	IgG4-Related Disease. <i>Medicine (United States)</i> , 2015, 94, e1275.	0.4	98
35	Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome. <i>Clinical Rheumatology</i> , 2006, 25, 341-346.	1.0	88
36	Sarcoidosis or Sjögren Syndrome?. <i>Medicine (United States)</i> , 2004, 83, 85-95.	0.4	83

#	ARTICLE	IF	CITATIONS
37	Thyroid disease in Sjögren's syndrome. <i>Clinical Rheumatology</i> , 2007, 26, 1601-1606.	1.0	83
38	Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients. <i>Lupus</i> , 2010, 19, 941-948.	0.8	74
39	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	1.8	73
40	Monoclonal gammopathy related to Sjögren syndrome: A key marker of disease prognosis and outcomes. <i>Journal of Autoimmunity</i> , 2012, 39, 43-48.	3.0	70
41	Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 391-405.	1.3	70
42	Life-Threatening Cryoglobulinemic Patients With Hepatitis C. <i>Medicine (United States)</i> , 2013, 92, 273-284.	0.4	69
43	Advances in the understanding and treatment of systemic complications in Sjögren's syndrome. <i>Current Opinion in Rheumatology</i> , 2014, 26, 520-527.	2.0	67
44	Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 2007, 57, 161-170.	6.7	66
45	IgG4-related disease: Advances in the diagnosis and treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 261-278.	1.4	63
46	Vasculitis induced by tumor necrosis factor-targeted therapies. <i>Current Rheumatology Reports</i> , 2008, 10, 442-448.	2.1	61
47	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019, 5, e001064.	1.8	53
48	Haemophagocytic syndrome and COVID-19. <i>Clinical Rheumatology</i> , 2021, 40, 1233-1244.	1.0	53
49	Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 391-399.	1.6	52
50	Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. <i>British Journal of Rheumatology</i> , 2004, 43, 1454-1456.	2.5	51
51	Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. <i>Rheumatology</i> , 2016, 55, 1443-1451.	0.9	51
52	Outcomes in Biopsy-Proven Lupus Nephritis. <i>Medicine (United States)</i> , 2010, 89, 300-307.	0.4	49
53	Emerging biological therapies in primary Sjögren's syndrome. <i>Rheumatology</i> , 2007, 46, 1389-1396.	0.9	48
54	Clinical and Prognostic Significance of Parotid Scintigraphy in 405 Patients with Primary Sjögren's Syndrome. <i>Journal of Rheumatology</i> , 2010, 37, 585-590.	1.0	48

#	ARTICLE	IF	CITATIONS
55	Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 279-289.	0.9	47
56	Circulating Monoclonal Immunoglobulins in Sjögren Syndrome. <i>Medicine (United States)</i> , 2005, 84, 90-97.	0.4	46
57	The Burden of Comorbidity and Complexity in Sarcoidosis: Impact of Associated Chronic Diseases. <i>Lung</i> , 2018, 196, 239-248.	1.4	46
58	Annular erythema in primary Sjögren's syndrome: description of 43 non-Asian cases. <i>Lupus</i> , 2014, 23, 166-175.	0.8	43
59	High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression. <i>Journal of Rheumatology</i> , 2007, 34, 754-61.	1.0	42
60	Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2007, 46, 76-80.	0.9	40
61	Sjögren Syndrome or Sjögren Disease? The Histological and Immunological Bias Caused by the 2002 Criteria. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 38, 178-185.	2.9	39
62	White matter abnormalities in primary Sjögren syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 433-443.	0.2	39
63	Rituximab Therapy in Lupus Nephritis: Current Clinical Evidence. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 159-169.	2.9	37
64	Sarcoidosis: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2431-2448.	0.9	37
65	Prevalence and Clinical Relevance of Autoimmune Neutropenia in Patients with Primary Sjögren's Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 38, 389-395.	1.6	36
66	Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 267-276.	1.2	35
67	Letter to the Editor. <i>Lupus</i> , 2004, 13, 969-971.	0.8	33
68	Chronic hepatitis B virus infection in Sjögren's syndrome. Prevalence and clinical significance in 603 patients. <i>Autoimmunity Reviews</i> , 2009, 8, 616-620.	2.5	33
69	How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 250.	1.6	33
70	Complexity, comorbidity, and health care costs associated with chronic widespread pain in primary care. <i>Pain</i> , 2016, 157, 818-826.	2.0	33
71	Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome. <i>Journal of Rheumatology</i> , 2006, 33, 1593-9.	1.0	32
72	Hepatitis C Virus and Sjögren's Syndrome: Trigger or Mimic?. <i>Rheumatic Disease Clinics of North America</i> , 2008, 34, 869-884.	0.8	31

#	ARTICLE	IF	CITATIONS
73	Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 686-92.	0.4	28
74	Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. <i>Journal of Viral Hepatitis</i> , 2007, 14, 070502203756003-???	1.0	25
75	Systemic autoimmune diseases in elderly patients:. <i>Autoimmunity Reviews</i> , 2004, 3, 376-382.	2.5	24
76	How the Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants. <i>Lung</i> , 2019, 197, 427-436.	1.4	24
77	Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 380-8.	0.4	24
78	Targeted therapy for systemic sclerosis: how close are we?. <i>Nature Reviews Rheumatology</i> , 2010, 6, 269-278.	3.5	23
79	Cytokines as therapeutic targets in primary Sjögren syndrome. , 2018, 184, 81-97.		23
80	Severe, life-threatening phenotype of primary Sjögren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 121-129.	0.4	21
81	Diagnosis of Liver Involvement in Primary Sjögren Syndrome. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 1, 94-102.	0.7	19
82	Coexistence of immune-mediated diseases in sarcoidosis. Frequency and clinical significance in 1737 patients. <i>Joint Bone Spine</i> , 2021, 88, 105236.	0.8	19
83	Lessons From Diseases Mimicking Sjögren's Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 275-283.	2.9	18
84	Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 1052-1064.	0.4	18
85	Mannose-binding lectin-low genotypes are associated with milder systemic and immunological disease expression in primary Sjögren's syndrome. <i>Rheumatology</i> , 2008, 48, 65-69.	0.9	17
86	Etanercept and uveitis: friends or foes?. <i>Current Medical Research and Opinion</i> , 2015, 31, 251-252.	0.9	16
87	Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects. <i>Drugs</i> , 2016, 76, 1601-1623.	4.9	15
88	Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 103-10.	0.4	15
89	Cryoglobulinemic disease. <i>Oncology</i> , 2013, 27, 1098-1105, 1110-6.	0.4	15
90	Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases. <i>Medicine (United States)</i> , 2020, 99, e18589.	0.4	14

#	ARTICLE	IF	CITATIONS
91	Etiopathogenic Role of Surfactant Protein D in the Clinical and Immunological Expression of Primary Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2015, 42, 111-118.	1.0	12
92	Phenotyping Sjögren's syndrome: towards a personalised management of the disease. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 198-209.	0.4	12
93	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	0.9	12
94	Diagnosing unexplained fever: can quick diagnosis units replace inpatient hospitalization?. <i>European Journal of Clinical Investigation</i> , 2014, 44, 707-718.	1.7	11
95	Practical guidelines for the early diagnosis of Sjögren's syndrome in primary healthcare. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 197-205.	0.4	8
96	New approaches in Sjögren's syndrome therapy. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 195-204.	1.3	6
97	Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1085-1101.	1.3	6
98	An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2359-2371.	0.9	6
99	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 97-106.	0.4	6
100	Primary Sjogren's syndrome. <i>Drugs of the Future</i> , 2008, 33, 0793.	0.0	3
101	Laboratory Abnormalities in Primary Sjögren's Syndrome. , 2011, , 347-366.		2
102	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94.	0.4	2
103	Autoimmune diseases in the elderly: systemic lupus erythematosus and Sjögren's syndrome. <i>Aging Health</i> , 2008, 4, 389-397.	0.3	1
104	Systemic Therapy of Sjögren Syndrome. <i>Rare Diseases of the Immune System</i> , 2016, , 383-398.	0.1	1
105	Immunological Tests in Primary Sjögren Syndrome. , 2011, , 401-416.		1
106	Chapter 9 Adrenal Involvement in Systemic Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 9, 95-101.	0.1	0
107	Punctal occlusion in Sjögren's syndrome needs clarification. <i>Nature Reviews Rheumatology</i> , 2012, 8, 752-752.	3.5	0
108	Sialadenitis. , 2021, , 48-63.		0

#	ARTICLE	IF	CITATIONS
109	Targeting B Cells in Other Systemic Autoimmune Diseases. Milestones in Drug Therapy, 2014, , 247-258.	0.1	0
110	Systemic Lupus Erythematosus: Indirect B-Cell Blocking. Milestones in Drug Therapy, 2014, , 79-95.	0.1	0
111	Practical guidelines for the early diagnosis of Sjögren's syndrome in primary healthcare. Clinical and Experimental Rheumatology, 2021, , .	0.4	0